Patent 10189832 was granted and assigned to Incyte on January, 2019 by the United States Patent and Trademark Office.
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.